These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 35431172)

  • 41. Nonculprit Lesion Plaque Morphology in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography Substudys.
    Pinilla-Echeverri N; Mehta SR; Wang J; Lavi S; Schampaert E; Cantor WJ; Bainey KR; Welsh RC; Kassam S; Mehran R; Storey RF; Nguyen H; Meeks B; Wood DA; Cairns JA; Sheth T
    Circ Cardiovasc Interv; 2020 Jul; 13(7):e008768. PubMed ID: 32646305
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
    Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
    Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
    [TBL] [Abstract][Full Text] [Related]  

  • 43. C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV.
    Nelson AJ; Puri R; Brennan DM; Anderson TJ; Cho L; Ballantyne CM; Kastelein JJ; Koenig W; Kassahun H; Somaratne RM; Wasserman SM; Nissen SE; Nicholls SJ
    Am J Prev Cardiol; 2020 Sep; 3():100091. PubMed ID: 34327467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Pérez de Isla L; Díaz-Díaz JL; Romero MJ; Muñiz-Grijalvo O; Mediavilla JD; Argüeso R; Sánchez Muñoz-Torrero JF; Rubio P; Álvarez-Baños P; Ponte P; Mañas D; Suárez Gutierrez L; Cepeda JM; Casañas M; Fuentes F; Guijarro C; Ángel Barba M; Saltijeral Cerezo A; Padró T; Mata P;
    Circulation; 2023 May; 147(19):1436-1443. PubMed ID: 37009731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS.
    Hattori K; Ozaki Y; Ismail TF; Okumura M; Naruse H; Kan S; Ishikawa M; Kawai T; Ohta M; Kawai H; Hashimoto T; Takagi Y; Ishii J; Serruys PW; Narula J
    JACC Cardiovasc Imaging; 2012 Feb; 5(2):169-77. PubMed ID: 22340823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequency, Predictors, Distribution, and Morphological Characteristics of Layered Culprit and Nonculprit Plaques of Patients With Acute Myocardial Infarction: In Vivo 3-Vessel Optical Coherence Tomography Study.
    Dai J; Fang C; Zhang S; Li L; Wang Y; Xing L; Yu H; Jiang S; Yin Y; Wang J; Wang Y; Guo J; Lei F; Liu H; Xu M; Ren X; Ma L; Wei G; Zhang S; Hou J; Mintz GS; Yu B
    Circ Cardiovasc Interv; 2020 Oct; 13(10):e009125. PubMed ID: 32957793
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial.
    Nicholls SJ; Puri R; Ballantyne CM; Jukema JW; Kastelein JJP; Koenig W; Wright RS; Kallend D; Wijngaard P; Borgman M; Wolski K; Nissen SE
    JAMA Cardiol; 2018 Sep; 3(9):806-814. PubMed ID: 30046837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.
    Komukai K; Kubo T; Kitabata H; Matsuo Y; Ozaki Y; Takarada S; Okumoto Y; Shiono Y; Orii M; Shimamura K; Ueno S; Yamano T; Tanimoto T; Ino Y; Yamaguchi T; Kumiko H; Tanaka A; Imanishi T; Akagi H; Akasaka T
    J Am Coll Cardiol; 2014 Dec; 64(21):2207-17. PubMed ID: 25456755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study.
    Montarello NJ; Singh K; Sinhal A; Wong DTL; Alcock R; Rajendran S; Dautov R; Barlis P; Patel S; Nidorf SM; Thompson PL; Salagaras T; Butters J; Nerlekar N; Di Giovanni G; Ottaway JL; Nicholls SJ; Psaltis PJ
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1175-1186. PubMed ID: 34432196
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
    Giugliano RP; Pedersen TR; Saver JL; Sever PS; Keech AC; Bohula EA; Murphy SA; Wasserman SM; Honarpour N; Wang H; Lira Pineda A; Sabatine MS;
    Stroke; 2020 May; 51(5):1546-1554. PubMed ID: 32312223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is the effect of atorvastatin 60 mg on stabilization of lipid-rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging.
    Xu M; Demuyakor A; Hu S; Liu H; Zhao C; Chen T; Qin Y; Xu Y; Feng X; Zeng M; Weng Z; Gao Z; Hou J; Jia H; Zhang S; Yu B
    Catheter Cardiovasc Interv; 2021 May; 97 Suppl 2():1097-1107. PubMed ID: 33864710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.
    Nicholls SJ; Andrews J; Kastelein JJP; Merkely B; Nissen SE; Ray KK; Schwartz GG; Worthley SG; Keyserling C; Dasseux JL; Griffith L; Kim SW; Janssan A; Di Giovanni G; Pisaniello AD; Scherer DJ; Psaltis PJ; Butters J
    JAMA Cardiol; 2018 Sep; 3(9):815-822. PubMed ID: 30046828
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome　- The ODYSSEY J-IVUS Trial.
    Ako J; Hibi K; Tsujita K; Hiro T; Morino Y; Kozuma K; Shinke T; Otake H; Uno K; Louie MJ; Takagi Y; Miyauchi K
    Circ J; 2019 Sep; 83(10):2025-2033. PubMed ID: 31434809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Morphological stabilization and regression of carotid plaque following therapy with evolocumab in a high-risk patient.
    Aranzulla TC; Musumeci G
    Catheter Cardiovasc Interv; 2021 May; 97(6):E835-E841. PubMed ID: 32845075
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes.
    Li T; Zhang Y; Cong H
    BMC Cardiovasc Disord; 2021 Jan; 21(1):19. PubMed ID: 33413096
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.
    Keech AC; Oyama K; Sever PS; Tang M; Murphy SA; Hirayama A; Lu C; Tay L; Deedwania PC; Siu CW; Lira Pineda A; Choi D; Charng MJ; Amerena J; Wan Ahmad WA; Chopra VK; Pedersen TR; Giugliano RP; Sabatine MS;
    Circ J; 2021 Oct; 85(11):2063-2070. PubMed ID: 33980763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.